Ginkgo Bioworks Holdings, Inc. (DNA) Stock Price & How to Invest

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a synthetic-biology company built around a horizontal cell-programming platform. Historically it reported in two segments: Cell Engineering, where its automated Foundry labs and Datapoints data service engineer and characterize cells for pharma, agriculture, food, and industrial customers; and Biosecurity, which provided pathogen monitoring and bioinformatics to governments and institutions. Cell Engineering revenue is generated through R&D service fees, its Datapoints biological-data offerings, and design, build, and support fees for its lab-automation (RAC) systems. Ginkgo went public via SPAC in 2021 at a lofty valuation that has since collapsed.

Since 2024, the story has been restructuring. Facing a low share price, the company completed a 1-for-40 reverse stock split in August 2024 to regain NYSE listing compliance, and it executed large workforce reductions and cost cuts while targeting adjusted-EBITDA breakeven by the end of 2026. In February 2026 it agreed to sell its non-core Biosecurity business, and that divestiture was completed in the first half of 2026, leaving Ginkgo focused on Cell Engineering and autonomous labs.

By mid-2026 the picture is a smaller, more focused, still-unprofitable company. Revenue has continued to shrink as legacy programs wind down, but management is betting on autonomous labs, its Nebula facility, the RAC automation systems, and Datapoints (which built recurring revenue and pharma relationships) as the future growth engine. The thesis is high-risk and hinges on whether AI-driven lab automation can scale into a durable, profitable business.

The dominant risk is cash burn against an uncertain path to profitability: Ginkgo remains deeply unprofitable, revenue has kept falling year over year, and it is spending down its cash while promising breakeven that has not yet arrived. If losses persist, further capital raises could dilute existing shareholders, and the company already completed a 1-for-40 reverse split after its post-SPAC valuation collapsed by billions, a reminder of how far expectations have reset. Customer concentration is a concern because a handful of large partners can drive results, and losing or delaying programs hits revenue hard. Competition spans synthetic-biology, lab-automation, and bio-AI players with more focus or funding. Execution risk on the autonomous-lab pivot is high, and the stock is speculative and volatile, so outcomes could be very good or very poor.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Ginkgo Bioworks Holdings, Inc.'s investor relations page or your broker.

• Revenue (TTM): Small and declining; Cell Engineering revenue fell year over year, and recent quarterly revenue dropped sharply versus the prior-year period
• Net loss / adjusted EBITDA: Still loss-making; large GAAP net losses continue, though narrower than before, with adjusted-EBITDA breakeven targeted by end of 2026
• Cash position: Several hundred million dollars in cash and marketable securities, funding operations while the company burns cash under its restructuring plan
• Path to profitability: Management guides to adjusted-EBITDA breakeven by the end of 2026 via cost cuts; sustained GAAP profitability is not yet in sight
• Market cap: A small-cap after the post-SPAC collapse and 1-for-40 reverse split; a fraction of its peak valuation
• Analyst coverage: Limited and cautious; the stock is widely treated as speculative and high-risk rather than a value or income holding

These are qualitative descriptions, not precise figures, and they are tied to the asOf date; verify live numbers before acting. Traditional earnings multiples do not apply to Ginkgo because it is unprofitable, so what matters is the trajectory of revenue, losses, cash burn, and progress toward the stated breakeven target. Because the company is pre-profit and pivoting its model, its valuation reflects belief in a future that has not yet been proven.

There are three common ways to get DNA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so DNA sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where DNA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Ginkgo Bioworks is a speculative, unprofitable bet on synthetic biology and lab automation. It has cut costs hard, divested its Biosecurity unit, and is chasing adjusted-EBITDA breakeven while revenue keeps falling. It rewards belief in the autonomous-lab thesis and punishes impatience with cash burn and dilution.